Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Want to see ALDX full AI Analyst Report?
Top Page
Aldeyra Therapeutics
(NASDAQ:ALDX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-16.67% Downside)
Action:Reiterated
Date:06/11/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and historical cash burn), compounded by a major regulatory setback (second FDA Complete Response Letter) that heightens execution risk. Technicals are neutral-to-weak on a longer-term basis, and valuation offers limited support given negative earnings and no dividend.
Positive Factors
RASP-modulation platform breadth
Aldeyra’s RASP-modulation platform is applicable across multiple therapeutic areas, reducing single-product dependency. Platform breadth supports durable value creation if one indication stalls, enabling internal pivots and multiple development commercialization pathways that sustain the pipeline over years.
Negative Factors
No revenue; persistent operating losses
As a clinical-stage biotech with no product revenue, Aldeyra relies on financing to fund operations. Persistent annual operating and net losses erode equity and mean long-term viability depends on successful late-stage outcomes or continued capital raises, a structurally risky funding model.
Read all positive and negative factors
Positive Factors
Negative Factors
RASP-modulation platform breadth
Aldeyra’s RASP-modulation platform is applicable across multiple therapeutic areas, reducing single-product dependency. Platform breadth supports durable value creation if one indication stalls, enabling internal pivots and multiple development commercialization pathways that sustain the pipeline over years.
Read all positive factors
Aldeyra Therapeutics (ALDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$103.15M
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)2.55
Revenue GrowthN/A
EPS Growth53.00%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume1,125,581
30 Day Avg. Volume1,007,539
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap-479.79K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit383.99M
Enterprise Value/Ebitda1.96M
Forecast
1Y Price Target
$5.50Price Target Upside205.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$21.72M
Aldeyra Therapeutics Business Overview & Revenue Model
Company Description
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive ald...
How the Company Makes Money
Aldeyra is not known to have a commercialized product generating recurring product sales; as a clinical-stage biotech, it primarily funds operations through capital raising (e.g., public equity offerings) and other financing activities rather than...
Aldeyra Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
57
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -128.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.22M | -31.69M | -53.68M | -35.21M | -60.07M | -55.77M |
| Net Income | -27.37M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
Balance Sheet | ||||||
| Total Assets | 66.48M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Cash, Cash Equivalents and Short-Term Investments | 65.00M | 70.04M | 101.15M | 142.82M | 174.30M | 229.79M |
| Total Debt | 15.51M | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Total Liabilities | 24.33M | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Stockholders Equity | 42.16M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
Cash Flow | ||||||
| Free Cash Flow | -25.99M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Operating Cash Flow | -25.99M | -33.35M | -43.21M | -30.33M | -56.64M | -42.56M |
| Investing Cash Flow | 40.45M | 47.74M | -44.92M | 30.00M | -29.95M | -7.81K |
| Financing Cash Flow | 191.89K | 1.12M | -171.42K | -1.27M | 1.22M | 194.50M |
Aldeyra Therapeutics Technical Analysis
Positive
1.80
Price Trends
1.68
Positive
3.01
Negative
4.05
Negative
Market Momentum
-0.01
Negative
51.76
Neutral
36.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Positive. The current price of 1.8 is above the 20-day moving average (MA) of 1.68, above the 50-day MA of 1.68, and below the 200-day MA of 4.05, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.76 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALDX.
Aldeyra Therapeutics Risk Analysis
Aldeyra Therapeutics disclosed 89 risk factors in its most recent earnings report. Aldeyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aldeyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $597.89M | -9.81 | -60.42% | ― | ― | 26.28% | |
52 Neutral | $736.78M | 7.29 | -54.39% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $238.38M | -3.86 | 85.78% | ― | 20.08% | 14.06% | |
45 Neutral | $329.81M | -1.44 | -181.70% | ― | ― | 17.61% | |
44 Neutral | $103.15M | -3.88 | >-0.01% | ― | ― | 53.00% | |
41 Neutral | $171.89M | -6.69 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
ALDX
Aldeyra Therapeutics
1.76
-1.02
-36.69%
OMER
Omeros
8.74
5.33
156.91%
GALT
Galectin Therapeutics
2.67
1.30
94.89%
FHTX
Foghorn Therapeutics
4.18
-0.14
-3.24%
CADL
Candel Therapeutics
8.56
3.43
66.86%
NMRA
Neumora Therapeutics, Inc.
1.78
0.94
111.90%
Aldeyra Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
Positive
Jun 10, 2026
On June 9, 2026, following its annual meeting of stockholders, Aldeyra Therapeutics appointed veteran biotech executive Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, determining that she meets SEC and Nasdaq indep...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Aldeyra Updates Reproxalap Outlook and Extends Cash Runway
Positive
May 1, 2026
On May 1, 2026, Aldeyra Therapeutics released an updated corporate overview detailing standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy trials of reproxalap in dr...
Executive/Board Changes
Aldeyra Therapeutics Announces Upcoming Board Member Departure
Neutral
Apr 20, 2026
On April 20, 2026, Aldeyra Therapeutics, Inc. announced that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders and will continue to serve until his term expires at that...
Business Operations and StrategyFinancial Disclosures
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
Positive
Apr 1, 2026
Aldeyra Therapeutics, Inc. previously entered into a Loan and Security Agreement in March 2019 with Hercules Capital, Inc. and a syndicate of lenders, known as the Hercules Credit Facility, which had a scheduled maturity date of April 1, 2026. On ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Issues Second Complete Response Letter for Reproxalap
Negative
Mar 17, 2026
On March 17, 2026, Aldeyra Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter rejecting the New Drug Application for reproxalap in dry eye disease, citing a lack of substantial evidence of efficacy,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.